Pharmaceuticals
turnover in the quarter was £3,882 million, down 12% AER, 8%
CER.
The
first quarter decline reflected the continued impact of the
COVID-19 pandemic. A strong prior year comparator included pandemic
related stock build at the end of the first quarter, accounting for
approximately 4 percentage points of the CER decline. In the
current quarter, the impact on the market environment included
lower demand for antibiotic products in International and Europe
regions.
New and
Specialty sales of £1,940 million declined 1% AER but grew 3%
CER, with ongoing growth from Respiratory, Immuno-inflammation and
Oncology partially offset by decline in HIV due to pandemic related
stock build in prior year and phasing of tenders in the
International region.
Respiratory
sales were up 19% AER, 24% CER, to £619 million, on growth of
Trelegy and Nucala and our Immuno-inflammation and
Oncology portfolios continue to show double digit growth. HIV sales
declined 15% AER, 11% CER, to £1,031 million, including the
impact of stock build last year, with growth in Dovato offset by Tivicay and Triumeq. Sales of Established
Pharmaceuticals declined 20% AER, 17% CER, to £1,942
million.
In the
US, sales declined 3% AER but grew 4% CER. Continued growth of
Nucala, Trelegy, Benlysta and Dovato was offset by the decline in
Triumeq and in Established
Pharmaceuticals, including the ongoing impact of generic
Ventolin.
In
Europe, sales declined 17% AER, 18% CER, with a strong comparator,
including COVID-19 pandemic related stocking at the end of the
quarter. This quarter, growth of Trelegy, Benlysta and HIV two-drug
regimens was offset by declines in Tivicay, Triumeq, and the Established
Pharmaceuticals portfolio. This portfolio was impacted by generic
competition including Seretide,
Duodart and Volibris, lower antibiotic demand, and
a one-off UK Relenza
contract last year.
International
declined 19% AER, 14% CER. Growth from the Respiratory portfolio
was offset by declines in HIV and Established Pharmaceuticals which
was impacted by COVID-19 suppressed antibiotics and dermatology
markets and increased generic competition in Japan on Xyzal and Avolve.
Respiratory
Total
Respiratory sales were up 19% AER, 24% CER, with growth from
Trelegy, Nucala and Anoro. International
Respiratory sales grew 32% AER, 38% CER including Nucala, up 27% AER, 33% CER, and
Trelegy up 76% AER, 82% CER
including the impact of Trelegy
Asthma launched in Japan in Q4 2020.
In
Europe, Respiratory grew 2% AER, but was flat at CER reflecting
strong comparator including additional demand related to COVID-19
pandemic related stocking at the end of the quarter. In the US,
Respiratory grew 24% AER, 32% CER, driven by Trelegy and Nucala and the impact of a prior period
RAR adjustment.
Sales
of Nucala were £254
million in the quarter and grew 21% AER, 26% CER, with US sales up
30% AER, 39% CER to £150 million and International sales of
£42 million grew 27% AER, 33% CER. Europe sales were flat at
AER, down 2% CER.
Trelegy sales were up 28% AER, 35% CER to £248 million
driven by growth in all regions. In the US, sales benefited from
the new asthma indication approved and launched in Q3 2020, with
sales up 29% AER, 37% CER. In Europe, sales grew 7% AER, 7% CER and
in International, where Trelegy asthma was approved in Japan in
Q4 2020, sales grew 76% AER, 82% CER to £30
million.
HIV
HIV
sales were £1,031 million with decline of 15% AER, 11% CER in
the quarter. The Q1 2020 sales comparator benefited from customer
stocking due to COVID-19, mainly in the US and Europe together with
timing of Tivicay tenders
in International. These two factors accounted for 8 and 2
percentage points of CER decline respectively, in addition to 1
percentage point of CER decline from the mature portfolio.
Triumeq sales were
£436 million, down 23% AER, 20% CER and Tivicay sales were £301 million,
down 27% AER,
24%
CER.
New HIV
products Juluca,
Dovato, Rukobia and Cabenuva delivered sales of £262
million representing 25% of the total HIV portfolio. Sales of the
two drug regimens Juluca
and Dovato were £112
million and £141 million respectively with combined growth of
36% AER, 41% CER. Rukobia
sales were £7 million. Cabenuva, the first long acting
injectable, launched in the US.
In the
US, total sales were £597 million with decline of 15% AER, 10%
CER. New HIV products delivered sales of £166 million,
including: Dovato £74
million growing 64% AER, 76% CER, Juluca £83 million declining 12%
AER, 5% CER, Rukobia
£7 million and Cabenuva £2 million. Combined
Tivicay and Triumeq sales were £419 million
declining 24% AER, 19% CER. In Europe, total sales were £287
million with decline of 10% AER, 12% CER. New HIV products
delivered sales of £84 million, including: Dovato £58 million growing
>100% AER, CER and Juluca £26 million growing 8% AER,
4% CER. Combined Tivicay
and Triumeq sales were
£196 million declining 25% AER, 26% CER.
Oncology
Sales
of Zejula, our PARP
inhibitor treatment for Ovarian cancer were £88 million in the
quarter, up 9% AER, 11% CER. Sales comprised £51 million in
the US and £36 million in Europe.
Blenrep for the treatment of patients with relapsed or
refractory multiple myeloma was approved and launched in the US and
Europe in Q3 2020 and reported sales of £21 million in the
quarter.
Immuno-inflammation
Sales
of Benlysta in the quarter
were up 18% AER, 25% CER to £178 million, including impact of
Lupus Nephritis launches in US and Japan.
Established
Pharmaceuticals
Sales
of Established Pharmaceuticals in the quarter were £1,942
million, down 20% AER, 17% CER.
Established
Respiratory products declined 14% AER, 11% CER to £1,127
million. This includes the ongoing impact of generic Ventolin in the US and Xyzal in Japan. Advair/Seretide sales declined 11% AER,
8% CER reflecting ongoing impact of generic
competition.
The
remainder of the Established Pharmaceuticals portfolio declined by
27% AER, 24% CER to £815 million on lower demand for
antibiotics during the COVID-19 pandemic period, the impact of
government mandated changes increasing use of generics in markets
including France, Japan and China, and a strong pre-COVID-19
comparator.
|